Scailyte bolsters Series A funding to USD 8 Million, accelerating the innovation in the immuno-oncology landscape

Scailyte, a driving force in biomarker discovery and translational platforms, has successfully extended its Series A funding to USD 8 million. This financial boost will accelerate Scailyte's impact within the immuno-oncology landscape, create new business partnerships, and expand its market footprint.

Committed to advancing the frontiers of single-cell omics and proprietary AI algorithms, Scailyte aims to solidify its position as a leader in healthcare. Scailyte's additional resources will play a key role in accelerating its impact within the immuno-oncology landscape, facilitating the expansion of business partnerships and broadening its market footprint. The company's commitment lies in consolidating its position as a premier biomarker discovery and translational platform, profiting from the capabilities of single-cell omics and proprietary AI algorithms.

Expressing his enthusiasm, Peter Nestorov, Scailyte's CEO & Co-Founder, states, "In the past year, we have gained significant commercial traction, validating the market need for an unbiased and powerful biomarker discovery approach, which delivers reliable and translatable insights from small patient populations. With the newly raised funds, we will expand our presence in the US market, seeking further partnerships with like-minded biotech and pharma companies in the precision oncology space."

Scailyte was ranked among the TOP 100 Swiss Startups from 2019 to 2021, participated in the Venture Leaders Life Science in 2019, and won the first step of the Venture Kick program in 2017.


Scailyte's team